Maurice B. Vincent

Rio De Janeiro, RJ 21941596, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Results from TRIUMPH [EUROPE], a Real-World Observational Study on the 3-Month Effectiveness of Galcanezumab Versus Traditional Oral Migraine Preventive Medications.

Results from TRIUMPH [EUROPE], a Real-World Observational Study on the 3-Month Effectiveness of Galcanezumab Versus Traditional Oral Migraine Preventive Medications.

Journal: Pain and therapy

Published: November 21, 2025

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study.

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study.

Journal: Headache

Published: September 24, 2025

Clinical Characteristics and Patient Burden of Cluster Headache in Brazil: A Real-World Study.

Clinical Characteristics and Patient Burden of Cluster Headache in Brazil: A Real-World Study.

Journal: Advances in therapy

Published: September 04, 2025

Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine.

Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine.

Journal: Cephalalgia : an international journal of headache

Published: August 21, 2025

Headache in pituitary adenomas: frequency, characteristics and outcome after treatment.

Headache in pituitary adenomas: frequency, characteristics and outcome after treatment.

Journal: Pituitary

Published: January 27, 2025

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study.

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study.

Journal: Headache

Published: January 08, 2025

Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention.

Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention.

Journal: The journal of headache and pain

Published: September 25, 2024

Patients' Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb).

Patients' Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb).

Journal: Pain and therapy

Published: May 01, 2024

Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience.

Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience.

Journal: Frontiers in neurology

Published: September 08, 2023

The not so hidden impact of interictal burden in migraine: A narrative review.

The not so hidden impact of interictal burden in migraine: A narrative review.

Journal: Frontiers in neurology

Published: August 30, 2022

Efficacy of lasmiditan for the acute treatment of perimenstrual migraine.

Efficacy of lasmiditan for the acute treatment of perimenstrual migraine.

Journal: Cephalalgia : an international journal of headache

Published: August 18, 2022

Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research.

Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research.

Journal: Pharmaceutical medicine

Published: June 02, 2022

Showing 1-12 of 57

Last Updated: 09/26/2026